GFAP and Cognitive impairment: In a very recent study, it has been shown that the administration of blocking anti-IL-17 antibody decreases the cognitive impairment and neuroinflammation induced by Aβ1−42 injection into cerebral ventricles of adult CD1 mice, as suggested by reduced Aβ1−42, glial fibrillary acidic protein (GFAP), S100 proteins, and inflammatory mediators and cytokines (205).